Bio

Supervisors

Education & Certifications

  • PhD, CUDIM - UdelaR, PET 11C Radiochemistry
  • MSc, UdelaR - College of Chemistry, Medicinal / Pharmaceutical Chemistry
  • BS, UdelaR - College of Chemistry, Chemistry

Contact

Links

Professional

Work Experience

  • Radiopharmacy Assistant, Uruguayan Center of Molecular Imaging (CUDIM) (February 1, 2011 - November 15, 2019)

    Location

    Montevideo, Uruguay

Publications

All Publications

  • Fully-automated radiosynthesis of the amyloid tracer [11C] PiB via direct [11C]CO2 fixation-reduction. EJNMMI radiopharmacy and chemistry Buccino, P. n., Savio, E. n., Porcal, W. n. 2019; 4 (1): 14

    Abstract

    The ?-amyloid radiotracer [11C] PiB is extensively used for the Positron Emission Tomography (PET) diagnosis of Alzheimer's Disease and related dementias. For clinical use, [11C] PiB is produced using the 11C-methylation method ([11C] Methyl iodide or [11C] methyl triflate as 11C-methylation agents), which represents the most employed 11C-labelling strategy for the synthesis of 11C-radiopharmaceuticals. Recently, the use of direct [11C]CO2 fixation for the syntheses of 11C-tracers has gained interest in the radiochemical community due to its importance in terms of radiochemical versatility and for permitting the direct employment of the cyclotron-produced precursor [11C]CO2. This paper presents an optimised alternative one-pot methodology of [11C]CO2 fixation-reduction for the rapid synthesis of [11C] PiB using an automated commercial platform and its quality control.[11C] PiB was obtained from a (25.9?±?13.2)% (Average?±?Variation Coefficient, n?=?3) (end of synthesis, decay corrected) radiochemical yield from trapped [11C]CO2 after 1?min of labelling time using PhSiH3 / TBAF as the fixation-reduction system in Diglyme at 150?°C. The radiochemical purity was higher than 95% in all cases, and the molar activity was (61.4?±?1.6) GBq/?mol. The radiochemical yield and activity (EOS) of formulated [11C] PiB from cyclotron-produced [11C]CO2 was (14.8?±?12.1)%, decay corrected) and 9.88?GBq (± 6.0%), respectively. These are higher values compared to that of the 11C-methylation method with [11C]CH3OTf (~?8.3%).The viability of the system PhSiH3 / TBAF to efficiently promote the radiosynthesis of [11C] PiB via direct [11C]CO2 fixation-reduction has been demonstrated. [11C] PiB was obtained through a fully automated radiosynthesis with a satisfactory yield, purity and molar activity. According to the results, the one-pot methodology employed could reliably yield sufficiently high tracer amounts for preclinical and clinical use.

    View details for DOI 10.1186/s41181-019-0065-4

    View details for PubMedID 31659494

    View details for PubMedCentralID PMC6635575

  • An efficient preparation of labelling precursor of [11C]L-deprenyl-D2 and automated radiosynthesis. EJNMMI radiopharmacy and chemistry Zirbesegger, K. n., Buccino, P. n., Kreimerman, I. n., Engler, H. n., Porcal, W. n., Savio, E. n. 2017; 2 (1): 10

    Abstract

    The synthesis of [11C]L-deprenyl-D2 for imaging of astrocytosis with positron emission tomography (PET) in neurodegenerative diseases has been previously reported. [11C]L-deprenyl-D2 radiosynthesis requires a precursor, L-nordeprenyl-D2, which has been previously synthesized from L-amphetamine as starting material with low overall yields. Here, we present an efficient synthesis of L-nordeprenyl-D2 organic precursor as free base and automated radiosynthesis of [11C]L-deprenyl-D2 for PET imaging of astrocytosis. The L-nordeprenyl-D2 precursor was synthesized from the easily commercial available and cheap reagent L-phenylalanine in five steps. Next, N-alkylation of L-nordeprenyl-D2 free base with [11C]MeOTf was optimized using the automated commercial platform GE TRACERlab® FX C Pro.A simple and efficient synthesis of L-nordeprenyl-D2 precursor of [11C]L-deprenyl-D2 as free base has been developed in five synthetic steps with an overall yield of 33%. The precursor as free base has been stable for 9 months stored at low temperature (-20 °C). The labelled product was obtained with 44 ± 13% (n = 12) (end of synthesis, decay corrected) radiochemical yield from [11C]MeI after 35 min synthesis time. The radiochemical purity was over 99% in all cases and specific activity was (170 ± 116) GBq/?mol.A high-yield synthesis of [11C]L-deprenyl-D2 has been achieved with high purity and specific activity. L-nordeprenyl-D2 precursor as free amine was applicable for automated production in a commercial synthesis module for preclinical and clinical application.

    View details for DOI 10.1186/s41181-017-0029-5

    View details for PubMedID 29503851

    View details for PubMedCentralID PMC5824701

  • Automated radiosynthesis of [C-11]L-deprenyl-D-2 and [C-11]D-deprenyl using a commercial platform APPLIED RADIATION AND ISOTOPES Buccino, P., Kreimerman, I., Zirbesegger, K., Porcal, W., Savio, E., Engler, H. 2016; 110: 47?52

    Abstract

    Two (11)C-labelled PET tracers, (R)-N-[(11)C]methyl-N-(3,3-dideuteropropargyl)-1-phenylpropan-2-amine ([(11)C]L-deprenyl-D2, [(11)C]DED) and (S)-N-[(11)C]methyl-N-propargyl-1-phenylpropan-2-amine ([(11)C]D-deprenyl, [(11)C]DDE) were synthesised. One step N-alkylation with [(11)C]MeI or [(11)C]MeOTf was performed using the automated platform TRACERlab® FX-C Pro. The labelled products were obtained with (37±15)% (n=10) (end of synthesis, decay corrected from [(11)C]MeI) radiochemical yields from [(11)C]MeI after 38±3min synthesis time. In all cases, radiochemical purity was over 99% when [(11)C]MeOTf was used. This synthesis using a commercial platform makes these tracers more accessible for clinical research purposes.

    View details for DOI 10.1016/j.apradiso.2015.12.051

    View details for Web of Science ID 000372380900006

    View details for PubMedID 26760951

  • Improving Production of C-11 to Achieve High Specific Labelled Radiopharmaceuticals Savio, E., Garcia, O., Trindade, V., Buccino, P., Giglio, J., Balter, H., Engler, H., AvilaRodriguez, M. A., ONeil, J. P., Barnhart, T. E., Dick, D. W., Koziorowski, J. M., Lapi, S. E., Lewis, J. S. AMER INST PHYSICS. 2012: 185?89

    View details for DOI 10.1063/1.4773964

    View details for Web of Science ID 000315028700035

  • Chemo-selective hydrolysis of the iminic moiety in salicylaldehyde semicarbazone promoted by ruthenium INORGANICA CHIMICA ACTA Vieites, M., Buccino, P., Otero, L., Gonzalez, M., Piro, O. E., Delgado, R. S., Anna, C. M., Barreiro, E. J., Cerecetto, H., Gambino, D. 2005; 358 (11): 3065?74

    View details for DOI 10.1016/j.ica.2005.04.021

    View details for Web of Science ID 000230179300012

  • Synthesis and biological properties of new 5-nitroindazole derivatives BIOORGANIC & MEDICINAL CHEMISTRY Aran, V. J., Ochoa, C., Boiani, L., Buccino, P., Cerecetto, H., Gerpe, A., Gonzalez, M., Montero, D., Nogal, J. J., Gomez-Barrio, A., Azqueta, A., de Cerain, A. L., Piro, O. E., Castellano, E. E. 2005; 13 (9): 3197?3207

    Abstract

    A series of new 3-alkoxy- or 3-hydroxy-1-[omega-(dialkylamino)alkyl]-5-nitroindazoles have been synthesized and their trichomonacidal, antichagasic and antineoplastic properties studied. Five derivatives (5, 6, 8, 9 and 17) showed remarkable trichomonacidal activity against Trichomonas vaginalis at 10 microg/mL concentration. Three compounds (8, 10, 11) exhibited interesting antichagasic activity and these same compounds moderate antineoplastic activity against TK-10 and HT-29 cell lines. Unspecific cytotoxicity against macrophages has also been evaluated and only compounds 9, 10 and 11 resulted cytotoxic at the higher dose evaluated (100 microg/mL), loosing cytotoxicity at lower doses. QSAR studies have been carried out. X-ray crystallographic study of compound 8 has been performed.

    View details for DOI 10.1016/j.bmc.2005.02.043

    View details for Web of Science ID 000228612100012

    View details for PubMedID 15809155

  • Opening of a vinyl aziridine with p-toluenesulfonamide under TBAF catalysis: synthesis of 3,4-diamino-3,4-dideoxy-l-chiro-inositol Tetrahedron Letters Paul, B. J., Hoobs, E., Buccino, P., Hudlicky, T. 2001; 42 (37)

    View details for DOI 10.1016/S0040-4039(01)01298-9

Footer Links:

Stanford Medicine Resources: